This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly
Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion, with up to $1 billion in milestone payments, to gain BPL-003, a Phase III fast-acting nasal spray for treatment-resistant depression. AtaiBeckley’s 15% stake gives founder Christian Angermayer about $360 million pre-tax. Phase III trials are expected to start in 2029.
How this was made
The 30-second read
Why it matters
For LLY, the deal adds a specific late-stage candidate (BPL-003) with an expected Phase III start in 2029. For ATAI, it is a liquidity event and valuation reset after a weak post-IPO performance.
Market read
This is a primary M&A disclosure with deal value, the transferred drug candidate, and Phase III timing, making it directly tradable for both acquirer and target risk/reward.
What to watch
The article highlights a shorter two-hour clinic window, but does not quantify clinical differentiation versus existing standards or the robustness of the overall treatment regimen, which is central to Phase III success.
Background
The article traces Christian Angermayer’s psychedelic involvement to the founding of Compass Pathways and Atai, culminating in Lilly’s acquisition of AtaiBeckley.
Ticker impact
Eli Lilly agreed to acquire AtaiBeckley for $2.8B plus up to $1B milestones, taking control of Phase III BPL-003.
Near-term sentiment likely positive for pipeline optionality, but magnitude depends on deal economics and Phase III risk.
The article discloses the headline transaction size, the specific asset (BPL-003), and Phase III timing expectations, which are actionable for biotech/pipeline positioning even if Lilly’s core earnings impact is not quantified.
AtaiBeckley was acquired by Eli Lilly in the largest psychedelics deal, with Angermayer’s 15% stake implying about $360M proceeds.
Stock reaction should be driven by deal terms, closing probability, and any implied valuation versus pre-deal trading levels.
The article provides deal consideration and the specific asset being transferred, but does not provide Atai’s exact pre-deal price or closing timeline, limiting precision on immediate price impact.
Market effects
Signals commercialization and Big Pharma willingness to fund rapid-acting psychedelic-like neuroplastogens, potentially improving deal appetite for similar assets.
Primarily US-listed biotech and pharma sentiment, with read-across to Nasdaq-listed psychedelics developers.
Reinforces global regulatory and commercialization pathways for psychedelic-derived medicines, influencing cross-border M&A expectations.
Counterpoint
Doblin’s concern is that Lilly’s approach may underweight therapy components, which could affect efficacy and regulatory outcomes for BPL-003.
Key entities
- acquirerEli Lilly
Agreed to acquire AtaiBeckley for $2.8B plus up to $1B milestones, targeting BPL-003 for treatment-resistant depression.
- targetAtaiBeckley
Psychedelics-focused company being acquired; develops BPL-003 (mebufotenin benzoate nasal spray) in Phase III.
- assetBPL-003
Fast-acting nasal spray containing mebufotenin benzoate, in Phase III development for treatment-resistant depression.
- investorChristian Angermayer
Holds a 15% stake in AtaiBeckley and is expected to receive around $360M pre-tax from the deal.
